ArticleGeburtshilfe und Frauenheilkunde2022
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT.
Abstract read
In one paragraph
Article in Geburtshilfe und Frauenheilkunde, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Trial
- Overall Survival in Metastatic Breast Cancer Patients: Real-World Data from 1,000 Patients Treated at the NCT Heidelberg between 2014 and 2022.Breast care (Basel, Switzerland) · 2026Article
- Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.Breast cancer research and treatment · 2026Observational
- Article
- CDK4/6 inhibitors for metastatic breast cancer in routine clinical practice in Spain: survey of patterns of use and oncologists' perceptions.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer - the SERAPHINA study.Journal of cancer research and clinical oncology · 2025Observational
- Update Breast Cancer 2024 Part 3 - Patients with Advanced Stage Breast Cancer.Geburtshilfe und Frauenheilkunde · 2025Article
- Cell-free tumor DNA analysis in advanced or metastatic breast cancer patients: mutation frequencies, testing intention, and clinical impact.Precision clinical medicine · 2025Article
- Impact of CCND1 amplification on the prognosis of hormone receptor-positive, HER2-negative breast cancer patients-correlation of clinical and pathological markers.Breast cancer research and treatment · 2025Article
- Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer.Geburtshilfe und Frauenheilkunde · 2024Article
- Update Breast Cancer 2024 Part 1 - Expert Opinion on Advanced Breast Cancer.Geburtshilfe und Frauenheilkunde · 2024Article
- Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry.Geburtshilfe und Frauenheilkunde · 2024Article
- CDK4/6 Inhibition - Therapy Sequences and the Quest to Find the Best Biomarkers - an Overview of Current Programs.Geburtshilfe und Frauenheilkunde · 2024Article
- Optimisation of Solid-Phase Extraction and LC-MS/MS Analysis of Six Breast Cancer Drugs in Patient Plasma Samples.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast Cancer.Geburtshilfe und Frauenheilkunde · 2023Article
- Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review.Targeted oncology · 2023Review
- CDK4/6 Inhibitors-Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer.Cancers · 2023Review
- Update Breast Cancer 2022 Part 6 - Advanced-Stage Breast Cancer.Geburtshilfe und Frauenheilkunde · 2023Article
- Update Breast Cancer 2022 Part 4 - Advanced-Stage Breast Cancer.Geburtshilfe und Frauenheilkunde · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Tobias EnglerDepartment of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.
Peter A FaschingDepartment of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Diana LüftnerImmanuel Hospital Märkische Schweiz & Medical University of Brandenburg Theodor-Fontane, Brandenburg, Germany.
Andreas D HartkopfDepartment of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.
Volkmar MüllerDepartment of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany.
Hans-Christian KolbergDepartment of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany.
Peyman HadjiFrankfurt Center for Bone Health, Frankfurt am Main, Germany; Philips-University of Marburg, Marburg, Germany.
Hans TeschOncology Practice at Bethanien Hospital, Frankfurt am Main, Germany.
Lothar HäberleDepartment of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Johannes EttlDepartment of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Markus WallwienerDepartment of Obstetrics and Gynecology, Heidelberg University Hospital, Heidelberg, Germany.
Matthias W BeckmannDepartment of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Alexander HeinDepartment of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Erik BellevilleClinSol GmbH & Co KG, Würzburg, Germany.
Sabrina UhrigDepartment of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Pauline WimbergerDepartment of Gynecology and Obstetrics, Carl Gustav Carus Faculty of Medicine and University Hospital, TU Dresden, Dresden, Germany.
Carsten HielscherGynäkologie Kompetenzzentrum - Onkologisches Zentrum Stralsund, Stralsund, Germany.
Christian M KurbacherDepartment of Gynecology I (Gynecologic Oncology), Gynecologic Center Bonn-Friedensplatz, Bonn, Germany.
Rachel WuerstleinDepartment of Gynecology and Obstetrics, Breast Center and CCC Munich, Munich University Hospital, Munich, Germany.
Michael UntchDepartment of Gynecology and Obstetrics, Helios Clinics Berlin-Buch, Berlin, Germany.
Florin-Andrei TaranDepartment of Obstetrics and Gynecology, Freiburg University Hospital, Freiburg, Germany.
Hans-Martin EnzingerDepartment of Gynecology and Obstetrics, Klinikum Bamberg, Sozialstiftung Bamberg, Bamberg, Germany.
Petra KrabischDepartment of Gynecology and Obstetrics, Klinikum Chemnitz gGmbH, Chemnitz, Germany.
Manfred WelslauOnkologie Aschaffenburg, Aschaffenburg, Germany.
Michael MaasbergMVZ Hämatologie-Onkologie Mayen/Koblenz GmbH, Mayen, Germany.
Dirk HempelOnkologiezentrum Donauwörth, Donauwörth, Germany.
Michael P LuxDepartment of Gynecology and Obstetrics, Frauenklinik St. Louise, Paderborn, Germany; Frauenklinik St. Josefs-Krankenhaus, Salzkotten, Germany; Kooperatives Brustzentrum Paderborn, St. Vincenz Krankenhaus GmbH, Paderborn, Germany.
Laura L MichelNational Center for Tumor Diseases, Heidelberg University Hospital, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Wolfgang JanniDepartment of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.
Diethelm WallwienerDepartment of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.
Sara Y BruckerDepartment of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.
Tanja N FehmDepartment of Gynecology and Obstetrics, Düsseldorf University Hospital, Düsseldorf, Germany.
Andreas SchneeweissNational Center for Tumor Diseases, Heidelberg University Hospital, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
advanced breast cancerCDK4/6 inhibitorchemotherapyendocrine treatmentreal world data
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.